Ascentage Pharma Group International (NASDAQ:AAPG) Receives “Buy” Rating from BTIG Research

BTIG Research reissued their buy rating on shares of Ascentage Pharma Group International (NASDAQ:AAPG) in a research report report published on Monday,Benzinga reports. BTIG Research currently has a $48.00 price target on the stock.

Several other research analysts also recently issued reports on the company. China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Finally, Rodman & Renshaw started coverage on Ascentage Pharma Group International in a research note on Tuesday, January 13th. They set a “buy” rating and a $48.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating and five have assigned a Buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $48.00.

Ascentage Pharma Group International Trading Up 0.5%

Ascentage Pharma Group International stock opened at $25.45 on Monday. Ascentage Pharma Group International has a one year low of $18.52 and a one year high of $48.45. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77. The business has a fifty day moving average of $24.11 and a two-hundred day moving average of $28.74.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The business had revenue of $24.72 million during the quarter.

Institutional Trading of Ascentage Pharma Group International

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS Group AG increased its position in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International during the 2nd quarter worth about $391,000. Citadel Advisors LLC purchased a new stake in Ascentage Pharma Group International during the 3rd quarter worth about $383,000. XY Capital Ltd increased its position in Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares in the last quarter. Finally, ABC Arbitrage SA purchased a new stake in Ascentage Pharma Group International during the 3rd quarter worth about $204,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.